Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Asia Pece und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Biomarkers, Tumor, Carrier Proteins, Glycoproteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Terry Fox Foundation, Associazione Italiana per la Ricerca sul Cancro, Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Bladder cancer incidence has recently risen, making it the ninth most diagnosed cancer, highlighting an urgent need for novel and effective diagnostic and therapeutic strategies to improve patient outcomes. Here, we report on a secreted glycoprotein, Galectin‐3‐binding protein (LGALS3BP), as a potential biomarker and therapeutic target for bladder cancer. We found a significantly elevated LGALS3BP expression in bladder cancer tissues, correlating with disease progression. Moreover, urinary and serum levels of LGALS3BP were significantly higher in patients compared to healthy individuals, with a strong correlation observed between elevated urinary protein levels and tumor grade. Of note, LGALS3BP produced by tumor cells treated with a mannosidase I inhibitor, Kifunensine, exhibited increased reactivity to a therapeutic antibody (denoted as “1959”), suggesting that glycosylation of LGALS3BP may influence antibody recognition and protein function. Furthermore, administration of 1959‐sss/DM4 antibody–drug conjugate in two xenograft mouse models of human bladder cancer resulted in complete inhibition of tumor growth. In summary, findings presented here highlight LGALS3BP as a promising candidate for further investigation into its potential as a urinary biomarker and a therapeutic target for bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy.
- Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy.
- Diagnostic Molecular Pathology, Unit of Anatomic Pathology, SS Annunziata Hospital, Chieti, 66100, Italy.
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada.
- Vancouver Prostate Centre, Vancouver, V6H 3Z6, BC, Canada.
- Department of Medical Oral Science and Biotechnology, G. d'Annunzio University, Chieti, 66100, Italy.
ORCID-Profile: Gianluca Sala
Förderung
- Terry Fox Foundation
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Pece, A., Lovato, G., Cela, I., Mercatelli, A., Ferro, B., Nikkola, J., Pagotto, S., Grottola, T., De Laurenzi, V., Cicchetti, R., Marchetti, A., Schips, L., Lattanzio, R., Iacobelli, S., Capone, E., Black, P., Daugaard, M., Marchioni, M., & Sala, G. (2026). Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. Molecular Oncology. https://doi.org/10.1002/1878-0261.70140
Vancouver
Pece A, Lovato G, Cela I, Mercatelli A, Ferro B, Nikkola J, et al. Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. Molecular Oncology. 2026. doi:10.1002/1878-0261.70140
BibTeX
@article{Pece2026,
author = {Pece, Asia and Lovato, Giulio and Cela, Ilaria and Mercatelli, Arianna and Ferro, Benedetta and Nikkola, Jussi and Pagotto, Sara and Grottola, Tommaso and De Laurenzi, Vincenzo and Cicchetti, Rossella and Marchetti, Antonio and Schips, Luigi and Lattanzio, Rossano and Iacobelli, Stefano and Capone, Emily and Black, Peter and Daugaard, Mads and Marchioni, Michele and Sala, Gianluca},
title = {Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70140}
}
EUVIMED